XmAb 942
Alternative Names: XmAb-942Latest Information Update: 14 Oct 2024
At a glance
- Originator Xencor
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 10 Oct 2024 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Inflammatory bowel disease released by Xencor
- 09 Sep 2024 Preclinical trials in Inflammatory bowel diseases in USA (Parenteral)
- 09 Sep 2024 Pharmacokinetics data from a preclinical trial in Inflammatory bowel disease released by Xencor